v3.26.1
Stockholders’ Equity and Stock-Based Compensation
6 Months Ended
Jun. 30, 2026
Stockholders’ Equity and Stock-Based Compensation [Abstract]  
STOCKHOLDERS’ EQUITY AND STOCK-BASED COMPENSATION

NOTE 11 – STOCKHOLDERS’ EQUITY AND STOCK-BASED COMPENSATION

Stockholders’ Equity

As of June 30, 2026 and December 31, 2025, the Company had 1,200,000,000 shares of Common Stock authorized for issuance, of which 529,838,610 and 380,763,481 shares of our Common Stock were issued and outstanding, respectively.

As of June 30, 2026 and December 31, 2025, the Company had 10,000,000 shares of preferred stock, par value $0.0001, authorized, of which 5,000,000 shares are designated as Series A Convertible Preferred Stock (“Series A Preferred”) and 5,000,000 shares are non-designated (“blank check,” together with the Series A Preferred, the “Preferred Shares”) shares. As of June 30, 2026 and December 31, 2025, the Company had no preferred stock outstanding.

Stock Issued for Convertible Debt

During the three months ended June 30, 2025, the Company issued 33,584,247 shares of its Common Stock to the lenders in lieu of cash payments for $1.9 million of outstanding interest and $22.6 million of outstanding principal on the 2022 Convertible Exchange Notes, 2023 Additional Notes, and 2024 Additional Notes. During the six months ended June 30, 2025, the Company issued 66,906,644 shares of its Common Stock to the lenders in lieu of cash payments for $1.9 million of outstanding interest and $45.2 million of outstanding principal on the 2022 Convertible Exchange Notes, 2023 Additional Notes, and 2024 Additional Notes.

Sale of Common Stock and Capital Raises

January 2026 Offering

On January 12, 2026, the Company closed on an offering (the “January 2026 Offering”) for the sale of (i) 19,000,000 shares of Common Stock (the “2026 Shares”), (ii) pre-funded warrants to purchase up to 41,790,274 shares of Common Stock (the “2026 Pre-Funded Warrants”), and (iii) common warrants to purchase up to 121,580,548 shares of Common Stock (the “2026 Common Warrants”).

The January 2026 Offering price for (i) each 2026 Share and accompanying 2026 Common Warrant was $16.45 and (ii) each 2026 Pre-Funded Warrant and accompanying 2026 Common Warrant was $16.45 (with all but a nominal exercise price of $0.0001 per share prepaid as of the issuance date). The 2026 Pre-Funded Warrants were immediately exercisable and will expire seven years from the date of issuance. As of June 30, 2026, the 2026 Pre-Funded Warrants have been fully exercised. The 2026 Common Warrants have an exercise price of $28.00 per share, were immediately exercisable and will expire seven years from the date of issuance.

The 2026 Common Warrants may be cash settled, at the option of the holders, upon a change of control event. Because share settlement of the 2026 Common Warrants is not within the Company’s control, the 2026 Common Warrants were initially classified as a liability with a fair value of $1,194.0 million, and the Company recognized a loss of $234.9 million. Refer to Note 12 for further discussion of the warrant liability.

The net proceeds to the Company from the January 2026 Offering was $959.1 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company and excluding any proceeds that may be received from the exercise of the 2026 Common Warrants. The Company has used a portion of the proceeds, and intends to use the remaining proceeds, from the January 2026 Offering for corporate development and strategic growth, including acquisitions, joint ventures and investments.

The table below details the net proceeds of the January 2026 Offering.

 

(dollars in thousands)

 

 

 

Gross proceeds

 

$

999,996

 

Offering costs:

 

 

 

Underwriting discounts and commissions

 

 

(40,000

)

Other offering costs

 

 

(892

)

Net proceeds

 

$

959,104

 

Noncontrolling Interests

 

Noncontrolling Interest in OAS

On September 11, 2025, certain OAS warrant holders exercised their warrants for 669,643 shares of OAS Common Stock for exercise proceeds of $1.2 million, of which $0.3 million was attributed to noncontrolling interest in OAS, representing an ownership interest of approximately 0.77% in OAS. The Company retained a controlling interest of approximately 99.23% in OAS. The transaction was accounted for as an equity transaction in accordance with ASC 810-10-45-23, with no gain or loss recognized in the consolidated statements of operations for year ended December 31, 2025.

On December 17, 2025, in conjunction with the OAS Exchange, 44,643 shares of OAS Common Stock were exchanged for Common Stock, reducing the noncontrolling interest in OAS to 0.71%. For the three and six months ended June 30, 2026, the Company attributed $35 thousand and $78 thousand of OAS’ net loss to the remaining noncontrolling interest in OAS, respectively. As of June 30, 2026 and December 31, 2025, the carrying value of the noncontrolling interest in OAS was $0.1 and $0.2 million, respectively.

Noncontrolling Interest in Insight

On October 27, 2025, the Company completed the acquisition of a controlling interest of 51% in Insight and recognized a noncontrolling interest for the remaining 49%. For the three months ended June 30, 2026, the Company attributed $0.2 million of Insight’s net loss and $0.3 million of foreign currency translation gains to the noncontrolling interest in Insight. For the six months ended June 30, 2026, the Company attributed $0.3 million of Insight’s net loss and $0.3 million of foreign currency translation gains to the noncontrolling interest in Insight. As of both June 30, 2026 and December 31, 2025, the carrying value of the noncontrolling interest in Insight was $3.8 million.

Noncontrolling Interest in SPO

In connection with the acquisition of SPO, Shamir retained a noncontrolling equity interest. Shamir has the right (the “First Put Option”) to cause the Company to purchase all (but not less than all) of the remaining issued and outstanding share capital of SPO held by Shamir at a purchase price of approximately $220.69 per share, including all capital notes of SPO then held by Shamir for no additional consideration. Shamir may exercise the First Put Option during the period commencing on October 15, 2025, and ending June 30, 2026. As of June 30, 2026, the First Put Option has expired.

As of December 31, 2025, the carrying value and redemption value of Shamir’s noncontrolling equity interest was $2.3 million. During the three months ended June 30, 2026, the Company attributed $1.3 million of SPO’s net loss and $86 thousand of foreign currency translation gains to the carrying value of Shamir’s noncontrolling interest. During the six months ended June 30, 2026, the Company attributed $2.4 million of SPO’s net loss and $87 thousand of foreign currency translation gains to the carrying value of Shamir’s noncontrolling interest. During the six months ended June 30, 2026, the noncontrolling interest was redeemable. Therefore the Company recorded accretion of $0.3 million and $1.6 million during the three and six months ended June 30, 2026, respectively, to increase the carrying amount of the noncontrolling interest to its redemption value. Upon expiration of the First Put Option, the Company reclassified the redeemable noncontrolling interest balance of $1.6 million to noncontrolling interest as of June 30, 2026.

Warrants to Purchase Common Stock of the Company

We use the Black-Scholes-Merton option model (the “Black-Scholes Model”) to determine the fair value of warrants to purchase Common Stock of the Company. The Black-Scholes Model is an acceptable model in accordance with U.S GAAP. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the term of the warrant.

The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the warrants. Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the expected life of the award. Our estimated volatility is an average of the historical volatility of peer entities whose stock prices were publicly available over a period equal to the expected life of the awards. We used the historical volatility of peer entities due to the lack of sufficient historical data of our stock price.

A summary of our Warrants activity and related information is as follows:

 

 

Number of
Shares
Under
Warrant

 

 

Weighted
Average
Exercise
Price

 

 

Weighted
Average
Remaining
Contractual
Life

 

Balance as of January 1, 2026

 

 

75,476,378

 

 

$

19.74

 

 

 

6.74

 

Granted

 

 

163,370,822

 

 

$

20.84

 

 

 

 

Exercised

 

 

(42,590,440

)

 

$

0.15

 

 

 

 

Canceled

 

 

-

 

 

$

-

 

 

 

 

Balance as of June 30, 2026

 

 

196,256,760

 

 

$

24.91

 

 

 

6.44

 

Vested and Exercisable as of June 30, 2026

 

 

196,230,207

 

 

$

24.91

 

 

 

6.44

 

Stock-Based Compensation

 

Equity Incentive Plans

In 2018, the Company’s stockholders adopted the 2018 Equity Incentive Plan, which has been subsequently amended (the “2018 Plan”), pursuant to which 3,333,334 shares of our Common Stock have been reserved for issuance to employees, including officers, directors and consultants. The 2018 Plan shall be administered by the Board, provided however, that the Board may delegate such administration to the compensation committee of the Board of the Company (the “Compensation Committee”). Subject to the provisions of the 2018 Plan, the Board and/or the Compensation Committee shall have authority to grant, in its discretion, incentive stock options, or non-statutory options, stock awards or restricted stock purchase offers (“Equity Awards”). As of June 30, 2026, the balance available to be issued under the 2018 Plan was 347,412 shares.

In 2021, the Company’s stockholders adopted the Ondas Inc. 2021 Stock Incentive Plan, which has been subsequently amended (the “2021 Plan”), pursuant to which 81,000,000 shares of our Common Stock have been reserved for issuance to employees, including officers, directors and consultants. The purpose of the 2021 Plan is to enable the Company to attract, retain, reward, and motivate eligible individuals by providing them with an opportunity to acquire or increase a proprietary interest in the Company and to incentivize them to expend maximum efforts for the growth and success of the Company, so as to strengthen the mutuality of the interests between the eligible individuals and the stockholders of the Company. The 2021 Plan provides for the issuance of awards including stock options, stock appreciation rights, restricted stock, restricted stock units, and performance awards. As of June 30, 2026, the balance available to be issued under the 2021 Plan was 11,226,808 shares.

Stock Options to Purchase Common Stock

The Company awards stock options to certain employees, directors, and consultants, which represent the right to purchase common shares on the date of exercise at a stated exercise price. Stock options granted to employees generally vest over a two to four-year period and are contingent on ongoing employment. Compensation expense related to these awards is recognized straight-line over the applicable vesting period. Stock options granted to consultants are subject to the attainment of pre-established performance conditions. The actual number of shares subject to the award is determined at the end of the performance period and may range from zero to 100% of the target shares granted depending upon the terms of the award. Compensation expense related to these awards is recognized when the performance conditions are satisfied.

The assumptions used in the Black-Scholes Model are set forth in the table below.

 

 

Six Months Ended
June 30,

 

2026

 

2025

Risk-free interest rate

 

3.69-4.25%

 

4.42-4.65%

Volatility

 

65.98-77.49%

 

59.05-88.69%

Expected life in years

 

5.17-5.88

 

5.00-5.77

Dividend yield

 

-%

 

-%

A summary of our option activity and related information is as follows:

 

 

Number of
Shares
Under
Option

 

 

Weighted
Average
Exercise
Price

 

 

Weighted
Average
Remaining
Contractual
Life

 

Balance as of January 1, 2026

 

 

20,014,381

 

 

$

3.72

 

 

 

8.16

 

Granted

 

 

11,457,727

 

 

$

10.51

 

 

 

 

Exercised

 

 

(2,517,970

)

 

$

2.34

 

 

 

 

Forfeited

 

 

(1,067,560

)

 

$

4.15

 

 

 

 

Canceled

 

 

(20,191

)

 

$

1.09

 

 

 

 

Balance as of June 30, 2026

 

 

27,866,387

 

 

$

6.62

 

 

 

8.31

 

Vested and Exercisable as of June 30, 2026

 

 

4,775,812

 

 

$

3.40

 

 

 

7.08

 

 

As of June 30, 2026, total unrecognized compensation expense related to non-vested options was $101.7 million which is expected to be recognized over a weighted-average period of 2.55 years. The weighted-average grant date fair value per option was $7.09 for options granted during the six months ended June 30, 2026.

Total stock-based compensation expense for stock options for the three and six months ended June 30, 2026 and 2025 is as follows:

 

 

Three Months Ended
June 30,

 

 

Six Months Ended
June 30,

 

(dollars in thousands)

 

2026

 

 

2025

 

 

2026

 

 

2025

 

General and administrative

 

$

4,856

 

 

$

876

 

 

$

8,801

 

 

$

1,664

 

Sales and marketing

 

 

1,272

 

 

 

136

 

 

 

2,086

 

 

 

134

 

Research and development

 

 

2,365

 

 

 

136

 

 

 

4,100

 

 

 

205

 

Cost of goods sold

 

 

707

 

 

 

125

 

 

 

1,282

 

 

 

194

 

Total stock-based compensation related to options

 

$

9,200

 

 

$

1,273

 

 

$

16,269

 

 

$

2,197

 

 

Restricted Stock Units

The Company awards Restricted Stock Units (“RSUs”) to certain employees and directors, which represent a right to receive common stock for each RSU that vests. RSUs generally vest over a one to four-year period and are contingent on ongoing employment or service as directors. Compensation expense related to these awards is recognized straight-line over the applicable vesting period.

A summary of our RSUs activity and related information is as follows:

 

 

RSUs

 

 

Weighted
Average
Grant Date
Fair Value

 

 

Weighted
Average
Vesting
Period
(Years)

 

Unvested balance at January 1, 2026

 

 

9,110,776

 

 

$

5.64

 

 

 

2.35

 

Granted

 

 

30,881,854

 

 

$

10.64

 

 

 

 

Vested

 

 

(6,472,288

)

 

$

7.68

 

 

 

 

Canceled

 

 

(238,109

)

 

$

7.97

 

 

 

 

Unvested balance at June 30, 2026

 

 

33,282,233

 

 

$

9.87

 

 

 

2.49

 

 

As of June 30, 2026, there were 33,431 restricted stock units that were vested but not yet released due to administrative timing. As of June 30, 2026, the unrecognized compensation expense for RSUs was $302.2 million, which is expected to be recognized over a weighted-average period of 2.32 years.

 

Total stock-based compensation expense for RSUs for the three and six months ended June 30, 2026 and 2025 is as follows:

 

 

Three Months Ended
June 30,

 

 

Six Months Ended
June 30,

 

(dollars in thousands)

 

2026

 

 

2025

 

 

2026

 

 

2025

 

General and administrative

 

$

56,636

 

 

$

637

 

 

$

67,186

 

 

$

924

 

Sales and marketing

 

 

1,098

 

 

 

57

 

 

 

1,825

 

 

 

211

 

Research and development

 

 

1,356

 

 

 

53

 

 

 

2,151

 

 

 

104

 

Cost of goods sold

 

 

859

 

 

 

68

 

 

 

1,322

 

 

 

133

 

Total stock-based compensation related to restricted stock units

 

$

59,949

 

 

$

815

 

 

$

72,484

 

 

$

1,372